Develops and commercializes innovative biopharmaceutical products, focusing on targeted oncology treatments.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company based in Newtown Square, Pennsylvania, dedicated to addressing unmet medical needs in cancer treatment across the United States. The company focuses on identifying, developing, and commercializing innovative therapies tailored for patients with various cancers, particularly non-small cell lung cancer (NSCLC) and other solid tumors.
ArriVent BioPharma's pipeline includes Furmonertinib, a next-generation tyrosine kinase inhibitor undergoing multiple clinical trials targeting epidermal growth factor receptor mutations (EFGRm) in NSCLC. These trials include a pivotal Phase 3 study for metastatic EFGRm NSCLC, as well as Phase 1b trials for NSCLC patients with other EGFR mutations and those with HER2 Exon 20 insertion mutations. The company's commitment to advancing targeted cancer therapies underscores its mission to improve outcomes and quality of life for cancer patients.
Established in 2021, ArriVent BioPharma has strategically positioned itself through collaborations with Aarvik Therapeutics Inc. to develop enhanced antibody drug conjugates (ADCs) and with Shanghai Allist Pharmaceuticals Co., Ltd. for the development and commercialization of Furmonertinib. These partnerships aim to leverage innovative research and development strategies to bring transformative therapies to market efficiently and effectively. With a robust pipeline and strategic alliances, ArriVent BioPharma continues to drive advancements in oncology treatment, poised to make a significant impact on cancer care globally.